Health Care · Surgical & Medical Instruments & Apparatus

KIDS ORTHOPEDIATRICS CORP SEC Filings & Insider Trading Activity 2026

company
CIK 142545089 filings
Russell 2000

KIDS at a glance

ORTHOPEDIATRICS CORP (KIDS, SEC CIK 1425450) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 27, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ORTHOPEDIATRICS CORP (KIDS) reported revenue of $236.3 million (up 15.4% from FY2024) and a net loss of $39.6 million. Diluted EPS was -$1.69.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding ORTHOPEDIATRICS CORP (KIDS) shares worth $119.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Pelizzon David R on September 10, 2026 of 302,369 shares at $21.01 per share.
  • In the last 90 days, KIDS insiders reported 0 open-market purchases ($0) and 21 open-market sales ($46.7M) on Form 4, a net sale of $46.7M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$236.3M
+15.4% vs prior year
Insiders · 90 days
0 buys · 21 sells
Net −$46.7M
13F holders
25 funds
$119.6M · +0 vs prior quarter
Latest 8-K
Oct 27, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to 10-K risk factors filed March 4, 2026

Management Discussion & Analysis

  • Q3 revenue $72.7M, up 19% YoY from $61.2M
  • Gross margin 74% vs 74% YoY; net loss $5.9M vs $11.8M
  • Best segment Trauma and deformity: $52.6M, up 19%; worst Sports medicine/other: unchanged
  • Operating cash flow $2.1M vs $(15.2)M; liquidity $44.9M at September 30
  • Near-term losses possible amid portfolio expansion and consigned-set investments; $20.0M delayed-draw facility undrawn

AI summary of the KIDS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 27, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $72.7M, up 19%, with Trauma and Deformity $52.6M and Scoliosis $19.2M driving growth
  • Adjusted EBITDA $6.9M, up from $6.2M, while gross margin held at 74%

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 earnings release for the quarter ended September 30, 2026
  • Unaudited condensed consolidated financial statements included in Exhibit 99.1
Filed Oct 27, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • 3Q26 revenue $72.7M, up 19%, with gross margin steady at 74%
  • Net loss narrowed to $5.9M from $11.8M, while diluted loss improved to $0.25 from $0.50

Item 7.01: Regulation FD Disclosure

  • Upcoming investor and analyst presentations by OrthoPediatrics executives
  • Exhibit 99.1 contains presentation materials that may shape near-term investor expectations
Filed Aug 4, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Upcoming investor and analyst presentations by OrthoPediatrics executives
  • Exhibit 99.1 contains presentation materials supporting management’s investor communications

AI summaries of KIDS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KIDS

Don't miss the next KIDS filing

  • Alerts as it files. A push when KIDS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KIDS, by share count.
  • Ask anything. An AI agent that reads every KIDS filing and answers with sources.

KIDS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Pelizzon David RSellSep 10, 2026$21.01
Squadron Capital LLCSellSep 10, 2026$21.01
Pritzker Jennifer N.SellSep 10, 2026$21.01
Pritzker Jennifer N.SellSep 2, 2026$23.35
Pelizzon David RSellSep 2, 2026$23.35
Squadron Capital LLCSellSep 2, 2026$23.35
Pritzker Jennifer N.SellSep 1, 2026$23.10
Pelizzon David RSellSep 1, 2026$23.10

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$204.7M$236.3M
Gross Profit-$148.6M$172.7M
Operating Income--$35.0M-$39.2M
Net Income--$37.8M-$39.6M
Gross Margin-72.6%73.1%
Op. Margin--17.1%-16.6%
Net Margin--18.5%-16.8%
Balance Sheet
Total Assets$438.7M$473.2M$508.6M
Equity$377.0M$354.6M$346.6M
ROE--10.7%-11.4%
Per Share
EPS-$-1.64$-1.69
Cash Flow
Operating CF--$27.0M-$4.9M
CapEx-$14.3M$11.1M

Source: XBRL data in ORTHOPEDIATRICS CORP (KIDS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KIDS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KIDS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$119.6M
Q2 202625$109.5M
Q1 202622$99.6M
Q4 202521$114.5M
Q3 202520$108.6M
Q2 202520$125.1M
Q1 202518$109.1M
Q4 202415$65.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 166 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KIDS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 28, 2026Analysis
8-KOct 27, 2026Analysis-
8-KOct 27, 2026Analysis-
4Sep 11, 2026--
4Sep 11, 2026--
4Sep 10, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 4, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Sep 1, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
10-QAug 5, 2026Analysis
8-KAug 4, 2026Analysis-
8-KAug 4, 2026Analysis-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-

Related Health Care companies

All Health Care →

KIDS SEC filings: frequently asked questions

Are KIDS insiders buying or selling?

In the last 90 days, ORTHOPEDIATRICS CORP (KIDS) officers, directors and 10% owners reported no open-market purchases and 21 open-market sales worth $46.7 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KIDS stock?

As of September 30, 2026, the largest ORTHOPEDIATRICS CORP (KIDS) holders among the 13F filers tracked by SignalX were BlackRock ($28.7 million), Vanguard Capital Management LLC ($16.7 million), Morgan Stanley ($13.4 million), Dimensional Fund Advisors ($11.1 million), State Street Corp ($9.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was KIDS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ORTHOPEDIATRICS CORP (KIDS) reported revenue of $236.3 million (up 15.4% from FY2024) and a net loss of $39.6 million. Diluted EPS was -$1.69. The figures come from the XBRL data in the 10-K.

What did KIDS report in its latest 8-K?

ORTHOPEDIATRICS CORP (KIDS) filed an 8-K on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $72.7M, up 19%, with Trauma and Deformity $52.6M and Scoliosis $19.2M driving growth.

What are the latest KIDS SEC filings?

ORTHOPEDIATRICS CORP (KIDS) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on October 27, 2026 and a Form 4 insider filing on September 11, 2026.

What is KIDS's SEC CIK number?

ORTHOPEDIATRICS CORP (KIDS)'s SEC Central Index Key (CIK) is 1425450. EDGAR lists every KIDS filing under that number.

Ask anything about KIDS

The research agent reads KIDS's filings, financials, insider trades and 13F holders, then answers with sources.